Pharmahungary Group Press release – multicenter preclinical proof-of-concept studies – unique service available via Pharmahungary Group

Budapest & Szeged, Hungary, 25th February, 2025.

Summary: Pharmahungary Group launched a unique service i.e. small and large animal multicenter studies for myocardial infarction and heart failure. The new service is available globally to all pharmaceuticals and biotechnology companies developing novel cardioprotective drugs. Multicenter studies represent a paradigm change in the preclinical proof-of-concept studies of cardioprotective drugs.

Although many cardioprotective interventions have been shown to limit infarct size in preclinical animal studies of acute myocardial ischemia/reperfusion injury, their clinical translation to patient benefit has been largely disappointing. A major factor is the lack of rigor and reproducibility in the preclinical studies. To address this, we have established the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) small animal multisite acute myocardial infarction network, with centralized randomization and blinded core laboratory infarct size analysis, and have validated the network using ischemic preconditioning.

Pharmahungary Group is offering a unique service in preclinical development, i.e. small and large animal multicenter studies for myocardial infarction and heart failure. The know-how and network of the sites were developed in a COST (EU-CARDIOPROTECTION, CA16225) and COST Innovators Grant (IMPACT, IG16225) led by Semmelweis University and University College London. Pharmahungary, the SME partner utilizes the preclinical multicenter trials according to the agreement with the consortium.

‘The IMPACT multisite mouse and rat AMI networks, with centralized randomization and blinded core infarct size analysis, were established to improve the reproducibility of cardioprotective interventions in preclinical studies and to facilitate the translation of these therapies for patient benefit.’ – concluded the vice-chairs of the consortium Prof. Péter Ferdinandy, MD, PhD, MBA, Founder & CEO of Pharmahungary Group and Prof. Dr. Derek Hausenloy, Professor, Signature Research Program in Cardiovascular & Metabolic Disorders, Duke-NUS Medical School.

See seminal references:
• Hernandez-Resendiz S et al, Basic Res Cardiol, 2025 – in press

• Kleinbongard P et al, Basic Res Cardiol, 2024 (PMID: 39422732)

• Sayour NV et al, Cardiovasc Res, 2023 (PMID: 36718529)

• Lecour S et al, Basic Res Cardiol, 2021 (PMID: 34515837)

About Pharmahungary Group
Pharmahungary Group is an ISO 9001:2015 certified Hungarian SME developing innovative in-house R&D projects for valorization and providing preclinical and clinical R&D services since 2001. Pharmahungary Group also focusing on developing miRNA therapeutics, based on the 2024 Nobel prize winner technology. More information: http://www.pharmahungary.com.

Contact Pharmahungary Group
Andras Nogradi, Business Development Director
Graphisoft Park, Zahony str. 7., Budapest, H-1031, Hungary, European Union
e-mail: businessdevelopment@pharmahungary.com